453 filings
EFFECT
PPBT
Purple Biotech Ltd
3 Apr 24
Notice of effectiveness
12:15am
POS AM
PPBT
Purple Biotech Ltd
28 Mar 24
Prospectus update (post-effective amendment)
4:01pm
6-K
PPBT
Purple Biotech Ltd
28 Mar 24
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
7:10am
6-K
PPBT
Purple Biotech Ltd
14 Mar 24
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
7:40am
6-K
PPBT
Purple Biotech Ltd
6 Mar 24
Report of Foreign Private Issuer
4:06pm
20-F
2023 FY
PPBT
Purple Biotech Ltd
Annual report (foreign)
5 Mar 24
4:00pm
6-K
PPBT
Purple Biotech Ltd
5 Mar 24
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
7:58am
6-K
PPBT
Purple Biotech Ltd
27 Feb 24
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
7:10am
SC 13G
Armistice Capital, LLC
14 Feb 24
PURPLE BIOTECH / ARMISTICE CAPITAL ownership change
3:49pm
6-K
PPBT
Purple Biotech Ltd
13 Feb 24
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
7:10am
6-K
PPBT
Purple Biotech Ltd
1 Feb 24
Report of Foreign Private Issuer
7:40am
6-K
PPBT
Purple Biotech Ltd
26 Jan 24
Report of Foreign Private Issuer
4:15pm
6-K
PPBT
Purple Biotech Ltd
20 Dec 23
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
8:06am
6-K
PPBT
Purple Biotech Ltd
14 Dec 23
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
7:00am
6-K
PPBT
Purple Biotech Ltd
21 Nov 23
Report of Foreign Private Issuer
4:00pm
6-K
PPBT
Purple Biotech Ltd
21 Nov 23
Purple Biotech Reports Third Quarter 2023 Financial Results
7:00am
EFFECT
PPBT
Purple Biotech Ltd
15 Nov 23
Notice of effectiveness
12:15am
424B3
PPBT
Purple Biotech Ltd
14 Nov 23
Prospectus supplement
4:13pm
F-1/A
PPBT
Purple Biotech Ltd
13 Nov 23
Registration statement (foreign) (amended)
4:11pm
CORRESP
PPBT
Purple Biotech Ltd
13 Nov 23
Correspondence with SEC
12:00am